{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T08:32:12Z","timestamp":1772785932510,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regulatory Toxicology and Pharmacology"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.yrtph.2016.06.001","type":"journal-article","created":{"date-parts":[[2016,6,3]],"date-time":"2016-06-03T16:34:24Z","timestamp":1464971664000},"page":"S39-S47","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"S1","title":["A harmonization effort for acceptable daily exposure application to pharmaceutical manufacturing \u2013 Operational considerations"],"prefix":"10.1016","volume":"79","author":[{"given":"Eileen P.","family":"Hayes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7106-830X","authenticated-orcid":false,"given":"Robert A.","family":"Jolly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9706-7583","authenticated-orcid":false,"given":"Ellen C.","family":"Faria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ester Lovsin","family":"Barle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel P.","family":"Bercu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lance R.","family":"Molnar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce D.","family":"Naumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Olson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison M.","family":"Pecquet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reena","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan K.","family":"Shipp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2149-8974","authenticated-orcid":false,"given":"Robert G.","family":"Sussman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia A.","family":"Weideman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yrtph.2016.06.001_bib1","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.yrtph.2012.08.002","article-title":"Advancing toxicology in RiskMAPP: setting ADEs based on the subsequent drug substance","volume":"65","author":"Bercu","year":"2013","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2016.06.001_bib2","series-title":"APIC Guidance on Aspects of Cleaning Validation in Active Pharmaceutical Ingredient Plants","author":"CEFIC","year":"2014"},{"key":"10.1016\/j.yrtph.2016.06.001_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yrtph.2005.06.010","article-title":"Application of the threshold of toxicological concern concept to pharmaceutical manufacturing operations","volume":"43","author":"Dolan","year":"2005","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2016.06.001_bib4","series-title":"Justification of Limits for Cleaning Validation in the Manufacture of Active Pharmaceutical Ingredients","author":"ECA Academy","year":"2007"},{"key":"10.1016\/j.yrtph.2016.06.001_bib6","series-title":"Guideline on Setting Health Based Exposure Limits for Use in Risk Identification in the Manufacture of Different Medicinal Products in Shared Facilities","author":"EMA","year":"2014"},{"key":"10.1016\/j.yrtph.2016.06.001_bib7","volume":"vol. 4","author":"EudraLex","year":"2015"},{"key":"10.1016\/j.yrtph.2016.06.001_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2016.05.026","article-title":"Using default methodology to derive the acceptable daily exposure (ADE)","author":"Faria","year":"2016","journal-title":"Manuscr. Accept. Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2016.06.001_bib9","article-title":"Determining cleaning validation acceptance limits for pharmaceutical manufacturing operations","volume":"17","author":"Fourman","year":"1993","journal-title":"Pharm. Technol."},{"key":"10.1016\/j.yrtph.2016.06.001_bib10","first-page":"317","article-title":"Scientific and practical considerations for the development of occupational exposure limits (OELs) for chemical substances","volume":"19","author":"Galer","year":"1992","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2016.06.001_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2016.05.022","article-title":"Special endpoint and product specific considerations in pharmaceutical ADE derivation","author":"Gould","year":"2016","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2016.06.001_bib11","series-title":"International Conference on Harmonisation (ICH), Geneva","article-title":"ICH guideline M7 on assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk","author":"ICH","year":"2014"},{"key":"10.1016\/j.yrtph.2016.06.001_bib12","series-title":"Guidance Document on Evaluating and Expressing Uncertainty in Hazard Characterization","author":"IPCS","year":"2014"},{"key":"10.1016\/j.yrtph.2016.06.001_bib13","series-title":"Baseline Pharmaceutical Engineering Guide, Volume 7, Risk-based Manufacture of Pharmaceutical Products: a Guide to Managing Risks Associated with Cross Contamination","author":"ISPE","year":"2010"},{"key":"10.1016\/j.yrtph.2016.06.001_bib14","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.fct.2003.08.006","article-title":"Structure-based thresholds of toxicological concern (TTC): guidance for application to substances present at low levels in the diet","volume":"42","author":"Kroes","year":"2004","journal-title":"Food Chem. Toxicol. Int. J. Publ. Br. Ind. Biol. Res. Assoc."},{"key":"10.1016\/j.yrtph.2016.06.001_bib15","article-title":"Methodology for assessing product inactivation during cleaning Part II: setting acceptance limits of biopharmaceutical product carryover for equipment cleaning","author":"Mott","year":"2013","journal-title":"J.\u00a0Valid. Technol."},{"key":"10.1016\/j.yrtph.2016.06.001_bib16","series-title":"Setting Priorities for Drinking Water Contaminants","author":"NAP","year":"1999"},{"key":"10.1016\/j.yrtph.2016.06.001_bib17","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1080\/10807039509380049","article-title":"Scientific basis for uncertainty factors used to establish occupational exposure limits for pharmaceutical active ingredients","volume":"1","author":"Naumann","year":"1995","journal-title":"Hum. Ecol. Risk Assess. Int. J."},{"key":"10.1016\/j.yrtph.2016.06.001_bib18","article-title":"A\u00a0harmonization effort for acceptable exposure methodology applied to pharmaceutical cleaning validation- communication with external stakeholders","author":"Olson","year":"2016","journal-title":"Manuscr. Accept. Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2016.06.001_bib19","series-title":"Points to Consider for Cleaning Validation","author":"PDA","year":"2012"},{"key":"10.1016\/j.yrtph.2016.06.001_bib20","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1093\/annhyg\/meu038","article-title":"Bioavailability of therapeutic proteins by inhalation\u2013worker safety aspects","volume":"58","author":"Pfister","year":"2014","journal-title":"Ann. Occup. Hyg."},{"key":"10.1016\/j.yrtph.2016.06.001_bib21","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1080\/15298668891379792","article-title":"Establishing airborne exposure control limits in the pharmaceutical industry","volume":"49","author":"Sargent","year":"1988","journal-title":"Am. Ind. Hyg. Assoc. J."},{"key":"10.1016\/j.yrtph.2016.06.001_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2016.05.029","article-title":"The regulatory framework for preventing cross-contamination of pharmaceutical products: history and considerations for the future","author":"Sargent","year":"2016","journal-title":"Manuscr. Accept. Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2016.06.001_bib24","first-page":"42","article-title":"Methodology for assessing product inactivation during cleaning Part I: experimental approach and analytical methods","volume":"18","author":"Sharnez","year":"2013","journal-title":"J.\u00a0Valid. Technol."},{"key":"10.1016\/j.yrtph.2016.06.001_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2016.05.023","article-title":"A\u00a0harmonization effort for exposure methodology \u2013 considerations for application of adjustment factors","author":"Sussman","year":"2016","journal-title":"Manuscr. Accept. Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2016.06.001_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2016.05.025","article-title":"Identifying and assessing highly hazardous drugs within quality risk management programs","author":"Sussman","year":"2016","journal-title":"Manuscr. Accept. Regul. Toxicol. Pharmacol."},{"issue":"1","key":"10.1016\/j.yrtph.2016.06.001_bib27","first-page":"58","article-title":"EMA guideline on setting health-based exposure limits","volume":"40","author":"Teasdale","year":"2015","journal-title":"Pharm. Tech."},{"key":"10.1016\/j.yrtph.2016.06.001_bib28","series-title":"Guidance for Industry PAT: a Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance","author":"US FDA","year":"2005"},{"key":"10.1016\/j.yrtph.2016.06.001_bib29","first-page":"1","article-title":"Cleaning validation for the 21st century: overview of new ISPE cleaning guide","volume":"31","author":"Walsh","year":"2011","journal-title":"Pharm. Eng."},{"key":"10.1016\/j.yrtph.2016.06.001_bib30","article-title":"Cleaning Validation for the 21st Century: Acceptance Limits for Active Pharmaceutical Ingredients (APIs): Part II","volume":"vol. 31","author":"Walsh","year":"2011"},{"key":"10.1016\/j.yrtph.2016.06.001_bib31","series-title":"Cleaning Validation for Biologics. Can Alternative Approaches to the PDE\/ADE Be Justified? BioPharm International, October 2015","author":"Walsh","year":"2015"},{"key":"10.1016\/j.yrtph.2016.06.001_bib32","first-page":"12","article-title":"Cleaning validation for the 21st century: acceptance limits for cleaning agents","author":"Walsh","year":"2013","journal-title":"Pharm. Eng."},{"key":"10.1016\/j.yrtph.2016.06.001_bib33","article-title":"Cleaning Limits: Why the 10 ppm criterion should be abandoned","author":"Crevoisier","year":"2016","journal-title":"Pharma Tech"}],"container-title":["Regulatory Toxicology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230016301593?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230016301593?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T07:40:58Z","timestamp":1536651658000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0273230016301593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":32,"alternative-id":["S0273230016301593"],"URL":"https:\/\/doi.org\/10.1016\/j.yrtph.2016.06.001","relation":{},"ISSN":["0273-2300"],"issn-type":[{"value":"0273-2300","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A harmonization effort for acceptable daily exposure application to pharmaceutical manufacturing \u2013 Operational considerations","name":"articletitle","label":"Article Title"},{"value":"Regulatory Toxicology and Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yrtph.2016.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}